PDT Partners’s Indivior Pharmaceuticals INDV Stock Holding History

PDT Partners’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.82M	Sell	117,378 -25,414	-18%	-$922K	0.25%	127
2026 Q1	$4.35M	Hold	142,792	–	–	0.26%	129
2025 Q4	$5.12M	Sell	142,792 -39,387	-22%	-$1.2M	0.33%	96
2025 Q3	$4.39M	Sell	182,179 -240	-0.1%	-$5.02K	0.28%	131
2025 Q2	$2.69M	Sell	182,419 -42,696	-19%	-$497K	0.15%	234
2025 Q1	$2.15M	Buy	225,115 +167,595	+291%	+$1.76M	0.15%	238
2024 Q4	$715K	Buy	57,520 +2,596	+5%	+$26.7K	0.06%	407
2024 Q3	$536K	Buy	+54,924	New	+$643K	0.05%	491

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PDT Partners's INDV Position: Q2 2026 in Review

PDT Partners reduced its Indivior Pharmaceuticals (INDV) stake by 18% in Q2 2026, selling an estimated $922K and leaving 117,378 shares worth $4.82M. The position accounts for 0.25% of the portfolio, ranked #127.

PDT Partners first reported a position in INDV in Q3 2024 and has held it in 8 quarters since. The position peaked at $5.12M in Q4 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

PDT Partners held 117,378 shares of Indivior Pharmaceuticals worth $4.82M as of Q2 2026.
PDT Partners sold 25,414 Indivior Pharmaceuticals shares in Q2 2026, an estimated $922K.
Indivior Pharmaceuticals made up 0.25% of PDT Partners's portfolio in Q2 2026, its #127 holding.
PDT Partners first reported a position in Indivior Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
PDT Partners's Indivior Pharmaceuticals position peaked at $5.12M in Q4 2025.
338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.